Aethlon Medical (NASDAQ:AEMD) Upgraded to “Sell” at Wall Street Zen

Wall Street Zen upgraded shares of Aethlon Medical (NASDAQ:AEMD) to a sell rating in a report issued on Saturday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Aethlon Medical in a report on Friday, July 17th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Aethlon Medical currently has a consensus rating of “Reduce”.

Aethlon Medical Price Performance

Shares of AEMD stock opened at $3.15 on Friday. The company has a market cap of $2.05 million, a price-to-earnings ratio of -0.21 and a beta of 1.41. The stock has a 50 day simple moving average of $5.60 and a 200-day simple moving average of $9.19. Aethlon Medical has a 1-year low of $2.63 and a 1-year high of $137.00.

Institutional Investors Weigh In On Aethlon Medical

A hedge fund recently bought a new stake in Aethlon Medical stock. Citadel Advisors LLC acquired a new position in shares of Aethlon Medical, Inc. (NASDAQ:AEMD) in the 3rd quarter, according to its most recent filing with the SEC. The fund acquired 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned approximately 36.57% of Aethlon Medical at the end of the most recent quarter. Institutional investors own 1.99% of the company’s stock.

About Aethlon Medical

Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical?stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life?threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.